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Abstract
Background: According to the Global Initiative of Asthma, the aim of asthma treatment is to gain and maintain
control. In the INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL
(LIAISON) study, we evaluated the level of asthma control and quality of life (QoL), as well as their determinants
and impact in a population consulting specialist settings.
Methods: LIAISON is a prospective, multicentre, observational study with a cross-sectional and a 12-month
longitudinal phase. Adults with an asthma diagnosis since at least 6 months, receiving the same asthma
treatment in the 4 weeks before enrolment were included. Asthma control was assessed with the 6-item
Asthma Control Questionnaire (ACQ) and QoL with the MiniAsthma Quality of Life Questionnaire (MiniAQLQ).
Results: Overall, 8111 asthmatic patients were enrolled in 12 European countries. Asthma control was suboptimal
in 56.5 % of patients and it was associated with poorer asthma-related QoL, higher risk of exacerbations and greater
consumption of healthcare resources.
Variables associated with suboptimal control were age, gender, obesity, smoking and comorbidities. Major
determinants of poor asthma control were seasonal worsening and persisting exposure to allergens/irritants/
triggers, followed by treatment-related issues.
Conclusions: The cross-sectional phase results confirm that suboptimal control is frequent and has a high
individual and economic impact.
Trial registration: The clinicaltrials.gov identifier is NCT01567280.
Background
The main goals of asthma management are to control
symptoms, prevent exacerbations, improve and maintain
lung function while minimizing side-effects of asthma
medications. Improvements in asthma control do not
only impact the patients’ daily life but are also associated
with a reduced risk of exacerbations and lung function
impairment. Additionally, gaining and maintaining asthma
control is expected to be cost-effective by reducing the
overall cost of asthma care and indirect costs related to
decreased productivity. However, in spite of the wide-
spread availability of therapies reported as highly effective
in randomised controlled trials [1], variable levels of asthma
control have been shown in several “real-life” studies using
well-validated self-assessment questionnaires, such as the
Asthma Control Questionnaire (ACQ) [2] and the Asthma
Control Test (ACT) [3]. In a recent study performed in
the Netherlands in 200 adult asthma patients, the per-
centage of patients with partly controlled or uncontrolled
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asthma was 35.5 % and 27.0 % respectively, as measured
by the ACQ [4]. In contrast, observational studies per-
formed in Italy reported about 35 % of suboptimal asthma
control [5, 6]. European-wide, population-based surveys
reported prevalence rates of unsatisfactory asthma control
levels ranging from 56.6 % [7] to 80.0 % [8, 9].
The discrepancies observed between the results of
randomised controlled trials and observational studies
are due to the different methodologies applied, the
former requiring more restrictive eligibility criteria for
the identification of a highly selected population and
closer control of single study subjects. In contrast,
“real-life” studies comprise larger and more diverse pa-
tient populations with/without comorbidities, different
levels of treatment adherence and with different ap-
proaches in the disease management depending on
various factors, like, among others, the qualification of
the treating physician, the availability of healthcare re-
sources, or the patient’s education to a healthy lifestyle.
Moreover, the use of different definitions of asthma
control and different tools to measure it makes it diffi-
cult to compare different results coming from studies
on asthma control [10].
The “INTERNATIONAL CROSS-SECTIONAL AND
LONGITUDINAL ASSESSMENT ON ASTHMA CON-
TROL” (LIAISON) study [11] was carried out to evalu-
ate the determinants and impact of suboptimal asthma
control and related quality of life (QoL).
Methods
Study design
LIAISON is a multinational, prospective, observational
cohort study designed to provide cross-sectional and
longitudinal information on asthma control. The study
was performed in Austria, Belgium, France, Germany,
Greece, Hungary, Italy, the Netherlands, Poland, Spain,
Turkey and the United Kingdom and recruited patients
between May 2012 and October 2013. In this first report
we describe data from the cross-sectional phase of the
study, which aimed at evaluating: (i) the proportion of
patients with controlled, partly controlled and uncon-
trolled asthma; (ii) health-related Quality of Life (HRQoL)
and its relation to the level of asthma control; and (iii) fac-
tors associated with suboptimal asthma control.
The study was conducted in accordance with the
current International Conference on Harmonization
Good Clinical Practice Guidelines, the World Medical
Association Declaration of Helsinki (59th WMA Gen-
eral Assembly, Seoul, October 2008) and all other ap-
plicable local laws and regulations. Patients gave
written informed consent and study approval was ob-
tained from all relevant local ethics committees and na-
tional regulatory authorities.
Study subjects
Male and female adult patients (smokers and non-smokers)
with a GINA-compliant diagnosis of asthma for at least
6 months and treated with the same anti-asthmatic drugs
in the last 4 weeks before enrolment were eligible for study
participation. Patients suffering from critical conditions and
illnesses that might have interfered (according to the doc-
tors’ judgment) with the study purposes were excluded.
Collected data and measurements
The following items were collected and their relations to
asthma control were analysed: demographic characteris-
tics (age, gender, body mass index, education level, living
environment, employment status, occupational exposure
to allergens/irritants/triggers, smoking habits, allergies,
concomitant diseases relevant to respiratory tract and
outpatients visits), characteristics of asthma (age and
severity at diagnosis, qualification of the physician and
investigations made for the diagnosis of asthma, current
severity of asthma symptoms, need of rescue medication
and participation in asthma education programs), the
reasons for poor control from the patient’s and the
physician’s perspective (according to their subjective
judgment; objective evidence were not required), the
anti-asthmatic treatments and the propensity to adhere
to therapy.
Self-administered tools were used for the assessment of
(i) asthma control (6-item ACQ), (ii) HRQoL (MiniAQLQ)
and (iii) propensity to adhere to therapy (4-item Morisky
Medication Adherence Scale, MMAS-4).
Number of spirometries, Peak Expiratory Flow (PEF),
Forced Expiratory Volume in 1 s (FEV1), Forced Vital
Capacity (FVC) and the ratio FEV1/FVC values related
to the last 12 weeks before the cross-sectional visit, were
collected and analysed, when available.
Healthcare resources utilization [emergency room (ER)
admittance, hospitalizations, days missed from work due
to asthma and support received by family] and severe
exacerbations (defined as deterioration of asthma resulting
in hospitalization or ER treatment or need of systemic
steroids for more than 3 days) in the last 12 months before
the cross-sectional visit, were collected and analysed.
Statistical analysis
The prevalence of patients with controlled, partly con-
trolled and uncontrolled asthma was calculated as the
proportion of patients with an ACQ score of ≤0.75,
>0.75–1.5 and ≥1.5, respectively, over the total of evaluable
patients at the cross-sectional phase visit.
Descriptive summary statistics [mean, standard devi-
ation (SD)] were applied for the MiniAQLQ score and
other continuous variables. For the ACQ score and other
categorical variables, frequencies and percentages were
provided. The Kruskal-Wallis test was used to compare
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continuous variables between the different asthma control
level groups. For the comparisons of categorical variables,
the Chi-square test was performed. The description of the
smoking habit considered current smokers, ex-smokers
and never-smokers as separate groups of patients.
The sample size was estimated in relation to the ex-
pected proportion of patients with controlled asthma at
the cross-sectional phase visit (approximately 37.5 %) [4]
and patients with partly controlled/uncontrolled asthma
at the cross-sectional phase visit reaching asthma control
after 12 months (approximately 45 %) [12]. Considering a
drop-out rate of 20 %, an initial patient population of
8150 subjects was calculated in order to have the expected
number of 4075 patients evaluable for the assessment of
the expected 45 % of patients reaching asthma control
at the end of the longitudinal phase with a precision of
± 1.5 % [two-sided 95 % confidence interval (CI)].
Considering the expected number of patients reaching
asthma control at the end of the longitudinal phase, the
distance from the boundaries of the two-sided 95 % CI
to the point estimate is 0.055 units for the MiniAQLQ
used for the evaluation of QoL, based on a SD of 1.21
units [13].
A multiple logistic regression model was built using
stepwise procedures to assess the variables independently
associated with asthma control and HRQoL.
Results
Description of the study population
Out of 8178 patients attending 153 outpatient hospitals
or General Practice clinics, 8111 were considered eligible
for the analysis.
The patients’ distribution by country in descending order
was: Italy 13.6 % (n = 1,101), Germany 13.2 % (n = 1,071),
Spain 12.8 % (n = 1,041), Poland 12.8 % (n = 1,037), France
10.5 % (n = 854), Hungary 10.5 % (n = 851), Turkey 5.4 %
(n = 439), the United Kingdom 4.9 % (n = 399), Belgium
4.7 % (n = 382), Greece 4.2 % (n = 339), Austria 4.0 %
(n = 324) and the Netherlands 3.4 % (n = 274).
Main patients’ characteristics are depicted in Table 1.
Asthma control and quality of life
Among 8111 patients, 43.5 % (n = 3,526) showed con-
trolled asthma, 18.0 % (n = 1,462) had partly controlled
asthma and 38.5 % (n = 3,123) uncontrolled asthma. The
mean (SD) of ACQ score was 0.27 (0.24), 1.07 (0.19) and
2.48 (0.80) in patients with controlled, partly controlled
and uncontrolled asthma, respectively.
Regarding Asthma Control Index by country, patients
in Italy and Spain had greater levels of asthma control,
whereas the lowest rates were observed in Hungary, The
Netherlands and France (Fig. 1).
Several demographic and clinical differences were
observed among patients of the three asthma control
levels, especially in the comparison of patients with
controlled vs uncontrolled asthma (Table 1).
Table 2 shows the relationship between the study
variables and the control of asthma. Obese patients
were significantly more likely to have partly controlled/
uncontrolled asthma compared to patients with normal
weight. The same was true for female patients vs male
patients as well as current smokers vs never-smokers.
As regards concomitant diseases, the risk of having
partly controlled/uncontrolled asthma was higher for
patients reporting respiratory infections, congestive
heart failure and psychological disturbances.
Better QoL was reported in patients with controlled
asthma and a positive correlation between the level of
asthma control and the QoL level was shown (Fig. 2 and
Additional file 1: Figure S1, respectively).
A higher score of MiniAQLQ was positively related to
younger age (18–39 years) as well as higher age (over
65 years) and male gender, while obesity was negatively
related to the MiniAQLQ score. As observed for asthma
control, a lower MiniAQLQ score was associated with
the presence of congestive heart failure, respiratory in-
fections and psychological disturbances (Table 3).
Characteristics of asthma
The diagnosis of asthma was made by a respiratory phys-
ician in 66.6 % of cases, while the remaining diagnoses
were confirmed by general practitioners (16.9 %) and other,
unspecified specialists (9.5 %). Such information was not
available for 7 % of participants. Investigations performed
as part of the diagnostic workup included spirometry (79.8
% of patients), allergy tests (53.1 %), chest x-ray (45.8 %),
PEF (26.6 %), IgE measurement (20.7 %), bronchial provo-
cation (17.1 %) and FENO (5.6 %). Asthma was predomin-
antly persistent at diagnosis (69.5 %) and was rated severe
in 23.6 % of uncontrolled patients (vs 12.7 % among con-
trolled patients).
Daily occurrence of asthma symptoms during the last
week before the visit was reported in 37.3 % of uncon-
trolled patients and need of daily rescue short-acting beta
agonist (SABA) use in 34.7 % of uncontrolled patients (vs
2.0 % and 2.7 % of patients with controlled asthma).
The percentage of patients reporting severe exacerba-
tions in the last 12 months before the visit was lower in
patients with controlled asthma compared to those with
partly controlled (p = 0.019) and uncontrolled disease (p <
0.001). One severe exacerbation was reported by 8.9 % of
controlled-asthma patients and 13.6 % of uncontrolled-
asthma patients. A higher proportion of uncontrolled pa-
tients suffered from more than two severe exacerbations
when compared to patients with controlled asthma (6.9 %
vs 1.5 %).
We found no difference in the percentage of patients
participating in an asthma education program across the
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Table 1 Demographic and clinical characteristics of participants
Controlled
n = 3526 (43.5)
Partly controlled
n = 1462 (18.0)
Uncontrolled
n = 3123 (38.5)
Overall
p-value*
Overall population
n = 8111 (100.0)
Age [years], mean (SD) 49 (16) 49 (16) 52 (15) <.001 50 (16)
Age categories (years), n (%) <.001
≤ 39 991 (30.1) 407 (30.0) 572 (21.9) 1970 (27.1)
40–64 1612 (49.0) 694 (51.1) 1519 (58.2) 3825 (52.7)
≥ 65 688 (20.9) 257 (18.9) 518 (19.9) 1463 (20.2)
Gender, n (%)
Female 2207 (62.8) 996 (68.3) 2184 (70.1) <.001 5387 (66.6)
Body mass index categories, n (%) <.001
Normal weight (≥18.5 and <25 kg/m2) 1469 (41.7) 545 (37.3) 1044 (33.4) 3058 (37.7)
Obese (≥30 kg/m2) 763 (21.7) 384 (26.3) 968 (31.0) 2115 (26.1)
Overweight (≥25 and <30 kg/m2) 1238 (35.1) 505 (34.5) 1069 (34.2) 2812 (34.7)
Underweight (<18.5 kg/m2) 53 (1.5) 28 (1.9) 42 (1.3) 123 (1.5)
Living environment, n (%) 0.038
Rural 871 (26.8) 412 (30.0) 792 (27.1) 2075 (27.5)
Urban 2374 (73.2) 960 (70.0) 2131 (72.9) 5465 (72.5)
Education, n (%) <.001
None 54 (1.8) 13 (1.0) 52 (1.9) 119 (1.7)
Primary/middle school 1122 (36.9) 528 (39.9) 1235 (45.7) 2885 (40.8)
High school 1179 (38.8) 461 (34.8) 890 (32.9) 2530 (35.8)
Graduate/Post Graduate 685 (22.5) 321 (24.3) 528 (19.5) 1534 (21.7)
Employment status, n (%) <.001
Employed 1811 (56.8) 734 (54.0) 1310 (45.1) 3855 (51.8)
Unemployed/housewife/student 602 (18.9) 263 (19.3) 553 (19.1) 1418 (19.0)
Retired/Unable to work 773 (24.3) 363 (26.7) 1039 (35.8) 2175 (29.2)
Occupational exposure to allergens/irritants among employed, n (%) 581 (32.1) 294 (40.1) 542 (41.4) 0.008 1417 (36.8)
Smoking habits, n (%) <.001
Never-smoker 2312 (66.6) 913 (63.8) 1966 (63.8) 5191 (65.0)
Current Smoker 314 (9.0) 182 (12.7) 425 (13.8) 921 (11.5)
Ex-Smokera 846 (24.4) 337 (23.5) 691 (22.4) 1874 (23.5)
Smoking history pack yearsb, mean (SD) 14 (14) 15 (14) 16 (16) <.001 15 (15)
Pack years ≥10, n (%) 588 (51.9) 280 (55.9) 641 (58.5) 0.007 1509 (55.3)
Allergies, n (%) 0.059
Yes 2327 (68.6) 953 (67.3) 1992 (65.8) 5272 (67.3)
No 1065 (31.4) 463 (32.7) 1035 (34.2) 2563 (32.7)
Frequent allergiesc
Inhalants, n (%) 2148 (92.3) 861 (90.3) 1783 (89.5) 0.005 4792 (90.9)
Drugs, n (%) 247 (10.6) 115 (12.1) 312 (15.7) <.001 674 (12.8)
Foods, n (%) 219 (9.4) 98 (10.3) 207 (10.4) 0.520 524 (9.9)
Comorbidities relevant to respiratory tractd, n (%)
Allergic rhinitis 976 (55.8) 452 (57.6) 860 (50.3) <.001 2288 (53.9)
Hypertension 508 (29.0) 247 (31.5) 629 (36.8) <.001 1384 (32.6)
Gastro − esophageal reflux 351 (20.1) 181 (23.1) 500 (29.2) <.001 1032 (24.3)
Chronic rhinosinusitis 259 (14.8) 96 (12.2) 276 (16.1) 0.040 631 (14.9)
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three groups (Additional file 1: Table S1). By contrast, a
difference was detected in investigators’ participation in
an asthma education program (46.6 % of controlled-
group vs 35.8 % of uncontrolled group).
The percentage of patients who underwent spirometry
in the last 12 weeks before the cross-sectional visit was
high (73.3 %), and higher in controlled vs uncontrolled
patients (75.0 % vs 70.6 %; p < 0.001). Lung function
was poorer in uncontrolled than in controlled patients
(Additional file 1: Table S2).
Factors associated with poor control
The main reasons for poor asthma control were ranked
with similar importance by patients and doctors, though
with different percentages (multiple answers were per-
mitted). Seasonal worsening and continued exposure to
allergens/irritants/triggers were identified most frequently
as the main reason for poor control with kappa coeffi-
cients indicating a substantial agreement between doctors
and patients. Interestingly, active smoking was considered
as a possible reason for poor control by only 10.1 % of
doctors and 7.4 % of patients.
If the treatment-related aspects (poor adherence, inad-
equate therapy, poor efficacy, inadequate inhalation tech-
nique, poor tolerability) are cumulated, treatment as a
whole can be upgraded as the most important factor for
poor asthma control representing 60.0 % of the reasons
expressed by doctors and 42.7 % of those expressed by
patients (Table 4).
Anti-asthma therapies and propensity to adhere
Fixed combinations of an inhaled corticosteroid (ICS) and a
long-acting beta agonist (LABA) were the most frequently
used current maintenance anti-asthmatic therapies (70.5 %
Table 1 Demographic and clinical characteristics of participants (Continued)
Psychological disturbances 145 (8.3) 95 (12.1) 333 (19.5) <.001 573 (13.5)
Respiratory infections 105 (6.0) 81 (10.3) 288 (16.8) <.001 474 (11.2)
Nasal polyposis 165 (9.4) 54 (6.9) 150 (8.8) 0.107 369 (8.7)
Obstruction Sleep Apnea Syndrome 74 (4.2) 33 (4.2) 92 (5.4) 0.216 199 (4.7)
Congestive heart failure 27 (1.5) 27 (3.4) 113 (6.6) <.001 167 (3.9)
Outpatients visitse
Mean (SD) 5.3 (5.6) 6.9 (6.5) 8.3 (7.7) <001 6.7 (6.8)
Patients with at least one visit, n (%) 3353 (95.1) 1399 (95.7) 2996 (95.9) 0.241 7748 (95.5)
The percentages have been calculated based on the number of available data for each variable
n number of patients, SD standard deviation
*p-value based on Chi-square for categorical variables and Kruskal-Wallis test for quantitative variables
aPatients who stopped smoking at least one year prior to study start
bRefers to current smokers and ex-smokers
cThe percentages are calculated based on the number of patients with allergies
dPatients could have more than one comorbidity
eIncluding visits to respiratory physician, allergologist, other specialist and general practitioner in the last 12 months
Fig. 1 Asthma Control Index among countries of the LIAISON study. The index was computed as the ratio of patients with controlled asthma
(6-item ACQ < 0.75) to patients with not well-controlled asthma (6-item ACQ ≤ 0.75). Asthma Control Index >1: greater proportion of patients
with controlled asthma. Asthma Control Index <1: greater proportion of patients with not well-controlled asthma
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of patients) followed by leukotriene receptor antagonists
(24.9 %) and ICS (24.4 %).
Among patients treated with ICS/LABA fixed combina-
tions, 35.0 % were on monotherapy, showing a percentage
of patients with controlled asthma of 50.6 %.
The mean MMAS-4 score was similar in the three sub-
groups of patients with an average rating = 1, corresponding
to an intermediate level of treatment adherence. However,
a higher rate of low adherence (score 3–4) was present in
patients with uncontrolled asthma compared to controlled
patients (16.3 % vs 13.0 %). No significant interaction was
found between the asthma control level and the non-
adherence categories (p = 0.398; Additional file 1: Table S3).
Healthcare resource consumption
The rate of patients who required hospitalization or ad-
mitted to an ER was significantly lower in patients with
controlled asthma than in those with partly controlled
and uncontrolled asthma, even if the total number of
events reported in the last 12 months was quite low (4.6
% of patients were hospitalized and 5.4 % admitted to
the ER). Significant differences among the three level of
control were detected considering the number of days
missed from work and the support received by the
family (Additional file 1: Table S4).
Differences between patients with controlled asthma
and those not-well controlled are shown by country in
Additional file 1: Table S5.
Discussion
Main findings
The results of the cross-sectional phase of the LIAISON
study show that a good control of asthma is achieved in
less than 50 % of patients attending specialist settings.
Suboptimal control was associated with poorer QoL, a
Table 2 Association between partly controlled/uncontrolled
asthma and demographics and comorbid conditions
Variable Odd ratio 95 % CI p-value
Gender
Male vs. Female 0.7286 0.6542, 0.8115 <.0001
Age [years]
18–39 vs. 40–64 0.8563 0.7576, 0.9678 0.0130
Over 65 vs. 40–64 0.7667 0.6707, 0.8766 0.0001
BMI
Overweight vs. Normal weight 1.2823 1.1365, 1.4467 <.0001
Obese vs. Normal weight 1.7139 1.4985, 1.9603 <.0001
Smoking habits
Current Smoker vs. Never smoker 1.5852 1.3474, 1.8649 <.0001
Environment
Rural vs. Urban 1.2419 1.1094, 1.3902 0.0002
Gastro-esophageal reflux
Yes vs. no 1.2480 1.0623, 1.4661 0.0070
Psychological disturbances
Yes vs. no 1.8714 1.5087, 2.3212 <.0001
Respiratory infections
Yes vs. no 2.4152 1.8992, 3.0715 <.0001
Congestive heart failure
Yes vs. no 3.4972 2.2226, 5.5027 <.0001
BMI body mass index, CI confidence interval
The reference group is made of controlled asthmatics. Subjects with available
data on variables included in the model were considered (n = 6421)
Variables included in the logistic regression model were identified after
stepwise selection
For each stepwise selection, it was considered 0.05 as significance level for
entering and for staying in the model
Fig. 2 Mean overall score of the Mini Asthma Quality of Life Questionnaire by asthma control level. *Overall p-value < .001
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higher risk of exacerbations and greater consumption
of healthcare resources. Suboptimal control of asthma
has also been reported in numerous previous studies
[4, 7, 8, 14, 15] based on different measures of asthma
control, sometimes self-reported by the patient.
Variables associated with control status were age, gen-
der, obesity, smoking, psychological status, history of
respiratory infections and congestive heart failure. The
same variables were associated with asthma-related QoL,
together with education level and allergies. In agreement
with previous findings [7], our results confirm that the
control of asthma is worse in women than in men, and
that the female gender increases the probability of un-
controlled asthma. Moreover, obesity and current smok-
ing were confirmed to be associated with worse control
of the disease. In contrast with the same study, our data
don’t show a relation between increased age and subopti-
mal control, which may relate to differences in population
characteristics (e.g., regarding comorbidities) and care
settings (the study by Demoly et al. was based on a self-
reported patient database).
General determinants of poor control
According to patients’ and doctors’ perspectives, major
determinants of poor asthma control were related to
environmental aspects followed by treatment-related is-
sues. The main reasons for poor asthma control were
reported to be related to seasonal worsening and contin-
ued exposure to allergens/irritants/triggers, as well as
comorbidities relevant to respiratory tract. Depression,
already reported as an independent risk factor for poor
asthma control [16], was indicated as a specific reason of
uncontrolled asthma in 8.5 % of the LIAISON patients as
well as in 9.9 % of doctors. Although about 11.5 % of pa-
tients were current smokers, only 7.4 % of patients (and
10.1 % of doctors) considered the active smoking as a pos-
sible cause of asthma worsening. Similarly, passive smok-
ing was recognized as a possible reason for poor control
by less than 10 % of patients and doctors.
Treatment-related factors are crucial for the control of
the disease, representing 60.0 % and 42.6 % of all reasons
for poor control (as expressed by doctors and patients,
respectively), as a whole. The risk of non-adherence was
low in the overall study population as well as in uncon-
trolled subjects (16.3 %). Two times more physicians
than patients identified poor adherence to therapy as a
potentially critical factor for poor asthma control, which
can relate to different perspectives and understanding
about the disease by the patients compared to the physi-
cians [17]. Although patient-physician communication did
not seem to represent a discriminant factor for asthma
control in our study, good communication is important to
establish effective collaboration and helps solving prob-
lems of proper inhalation technique like difficulties in
device handling [14, 18].
These considerations point to the interrelation of
various factors impacting on asthma control such as
the patients’ underestimation of their symptoms [15]
and the complexity of disease management in the pres-
ence of comorbidities and environmental/seasonal factors.
The fixed combination of inhaled corticosteroids and
long-acting beta-agonists was the most widely used ther-
apy in the LIAISON study. Although randomised con-
trolled clinical trials have demonstrated high efficacy and
tolerability of the available anti-asthma medications, real-
life data like the LIAISON study, still underline that medi-
cations alone are not sufficient to obtain control if other
factors are not sufficiently taken into consideration such
as the understanding of the particular characteristics of
Table 3 Relationship between quality of life by MiniAQLQ and
demographics and comorbid conditions
Variable Beta 95 % CI p-value
Gender
Male vs. Female 0.2638 0.1976, 0.3299 <.0001
Age [years]
18–39 vs. 40–64 0.2786 (0.2027, 0.3545) <.0001
Over 65 vs. 40–64 0.1677 (0.0861, 0.2493) <.0001
BMI
Obese vs. Normal weight −0.2346 (−0.3055, −0.1636) <.0001
Ethnicity
Asian vs. White −0.8009 −1.3949, −0.2069 0.0082
Smoking habits
Ex-Smoker vs. never-smoker 0.0991 (0.0264, 0.1717) 0.0075
Education
Graduate/Post Graduate vs.
Primary or middle school
0.3355 (0.2520, 0.4189) <.0001
High school vs. Primary or
middle school
0.2008 (0.1307, 0.2708) <.0001
Allergy to Inhalants
Yes vs. no −0.0942 (−0.1597, −0.0288) 0.0048
Psychological disturbances
Yes vs. no −0.5340 (−0.6497, −0.4184) <.0001
Gastro-esophageal reflux
Yes vs. no −0.1626 (−0.2565, −0.0688) 0.0007
Respiratory infections
Yes vs. no −0.5875 (−0.7151, −0.4599) <.0001
Congestive heart failure
Yes vs. no −0.6949 (−0.8963, −0.4935) <.0001
BMI body mass index, CI confidence interval
Subjects with available data on variables included in the model were
considered (n = 5618)
Variables included in the logistic regression model were identified after
stepwise selection. For each stepwise selection, it was considered 0.05 as
significance level for entering and for staying in the model
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each patient and a careful follow-up of the course of
disease.
Impact of poor asthma control
Importantly, the achievement of good asthma control in-
fluences the level of QoL, as shown in our study based on
the MiniAQLQ, as well as in other studies using generic
QoL tools [5, 19]. Other studies found that suboptimal
control also interacts with activity limitations, work prod-
uctivity or the frequency of emergency visits [15, 19]. Pre-
vious findings showed that both a history of past asthma
exacerbations and poor asthma control can increase the
risk of future asthma exacerbations [20, 21]. In this study,
we found a difference in severe exacerbations across the
asthma control levels but it has to be taken into account
that 12.6 % of patients with good asthma control reported
a history of severe exacerbation over the previous year.
Exacerbations, hospitalizations or ER admittance were
lower in controlled patients, confirming the importance of
asthma control also in terms of healthcare resource con-
sumption [5, 15, 19, 22]. Notably, a greater proportion of
controlled patients underwent a spirometry test in the last
12 weeks before the cross-sectional visit as compared to
uncontrolled patients.
Strengths and limitations
The data presented in this manuscript were analysed for
the whole study population but what should be taken into
account is that the management of patients with asthma as
well as the care settings are different among the countries
involved in the study. The differences among countries in-
volved is probably reflective of the point of care for patient
recruitment i.e., primary or secondary consult. Also, the
nature of these consults, whether routine or otherwise.
These populations are not a representative cohort and
larger studies are needed to address those factors. The
focus of this manuscript is to show the impact of asthma
control on individual quality of life as well as healthcare
resource utilization.
Some of the data analysed (comorbidities, severe exacer-
bations, emergency department visits or hospitalizations)
were reported by patients and could not be directly verified.
As an additional limitation, some comorbidities such as
rhinitis could impact the results. Unfortunately, chronic
obstructive pulmonary disease (COPD) was not included
in the recorded comorbidities, so it is not possible to ex-
clude that some patients had this concomitant diagnosis.
Conclusion
The LIAISON study is one of the largest observational
studies on characteristics and management of asthmatics
in Europe based on patient reported outcomes. The results
of the cross-sectional phase confirm that many patients
with asthma are not well-controlled in real-life despite the
wide availability of highly efficacious treatments. Poorer
control of asthma is associated with a worse QoL, an in-
creased risk of exacerbations and more consumption of
healthcare resources. Many reasons contribute to poorly
controlled asthma, both clinical (i.e., comorbidities) and be-
havioural (i.e., smoking or non-adherence). Their identifica-
tion could affect the achievement of asthma control, since
most risk factors are modifiable.
Moreover, we expect data analysis of the longitudinal
phase of LIAISON; characterizing partly controlled/
uncontrolled asthma over a one-year follow-up in the
near future, to be complementary and highly informative.
Additional file
Additional file 1: Figure S1. Scatter plot of ACQ and miniAQLQ scores.
Table S1. Characteristics of asthma. Table S2. Lung function. Table S3.
Propensity to adhere to therapy. Table S4. Healthcare resources
consumption. Table S5. Healthcare and economic resources
consumption by country. (DOCX 155 kb)
Table 4 Reasons for poor asthma control, according to patients’ and doctors’ perspective
Reasons for poor controla: n = 4585 Patients’ perspective
n (%)
Doctors’ perspective
n (%)
Kappa coefficientb
Seasonal worsening
Continued exposure to allergens/irritants/triggers
Comorbidities
Poor adherence to therapy
Inadequate therapy
Poor efficacy of therapy
Active smoking
Depression
Passive smoking
Inadequate inhalation technique
Poor patient-physician communication
Poor tolerability of therapy
Co-administration of drugs
Incorrect diagnosis
1848 (40.3)
1148 (25.0)
769 (16.8)
507 (11.1)
571 (12.5)
675 (14.7)
339 (7.4)
388 (8.5)
421 (9.2)
104 (2.3)
78 (1.7)
97 (2.1)
70 (1.5)
57 (1.2)
1756 (38.3)
1270 (27.7)
1028 (22.4)
965 (21.0)
868 (18.9)
622 (13.6)
462 (10.1)
453 (9.9)
319 (7.0)
195 (4.3)
197 (4.3)
100 (2.2)
68 (1.5)
40 (0.9)
0.72
0.73
0.68
0.47
0.56
0.53
0.81
0.67
0.64
0.39
0.27
0.44
0.55
0.30
N number of patients
aMore than one reason could be indicated
bKappa agreement interpretation: <0: poor, 0.01–0.20: slight, 0.21–0.40: fair, 0.41–0.60: moderate, 0.61–0.80: good, 0.81–1.00; very good
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